NephroCare India, a Kolkata-based renal care provider, has secured Rs 8.08 crore in a pre-IPO funding round as it looks to focus on its expansion plans.
Who are the Investors?
The funding round saw participation from Deepak Parekh, the former chairman of HDFC; Bharat Shah, chairman of HDFC Securities; and Rajendra Agarwal, founder and MD of Macleods Pharmaceuticals.
Focused on expansion
With the fresh capital, NephroCare India aims to establish 22 high-end kidney care facilities across India by March 2026. The immediate goal includes launching four centres by the end of the current fiscal year.
In a broader perspective, the company envisions setting up 300 NephroCare centres nationwide over the next 8-10 years.
Addressing a critical healthcare gap
The Company highlighted the dire need for expanded kidney care in India. With an estimated seven crore individuals suffering from chronic kidney diseases and a stark shortage of haemodialysis centres (approximately 12,881 nationwide), the demand for accessible and quality kidney care is immense. Nearly one in eleven Indians are at risk of renal failure, primarily due to diabetes and hypertension.
India, often referred to as the ‘diabetes capital of the world’, adds about 250,000 new dialysis-dependent patients each year due to advanced kidney conditions. This alarming statistic further emphasizes the urgent need for more infrastructure and facilities to combat the growing health crisis.
Join our new WhatsApp Channel for the latest startup news updates
